Table 1. Annual changes in characteristics of children hospitalized with an RSV infection.
| 2018 (n = 267) | 2019 (n = 285) | 2020 (n = 19) | 2021 (n = 263) | P-value | |
|---|---|---|---|---|---|
| Age: months, n (%) | |||||
| <3 months | 77 (28.8) | 70 (24.6) | 3 (15.8) | 73 (27.8) | 0.674 |
| 3–5 months | 30 (11.2) | 33 (11.6) | 3 (15.8) | 44 (16.7) | 0.0472 |
| 6–11 months | 39 (14.6) | 45 (15.8) | 5 (26.3) | 31 (11.8) | 0.168 |
| 12–23 months | 87 (32.6) | 89 (31.2) | 5 (26.3) | 50 (19.0) | 0.000123 |
| ≥24 months | 34 (12.7) | 48 (16.8) | 3 (15.8) | 65 (24.7) | 0.000919 |
| Sex: male, n (%) | 153 (57.3) | 153 (53.7) | 10 (52.6) | 142 (54.0) | 0.765 |
| Palivizumab indication | |||||
| n (%) | 8(3.0) | 4 (1.4) | 0 (0) | 2 (0.8) | 0.246 |
| not indicated | 259 (97.0) | 281 (98.6) | 19 (100.0) | 261 (99.2) | |
| Palivizumab prophylaxis | |||||
| n (%) | 5 (1.9) | 2 (0.7) | 0 (0) | 0 (0) | 0.105 |
| not administered | 262 (98.1) | 283 (99.3) | 19 (100.0) | 263 (100.0) | |
| Presence of siblings | |||||
| n (%) | 151 (56.6) | 164 (57.5) | 10 (52.6) | 187 (71.1) | 0.0154 |
| no siblings | 45 (16.9) | 44 (15.4) | 4 (21.1) | 31 (11.8) | |
| unknown | 71 (26.6) | 77 (27.0) | 5 (26.3) | 45 (17.1) | |
| Hospitalization duration | |||||
| mean days (SD) | 5.31 (1.97) | 5.50 (2.17) | 5.58 (1.61) | 5.52 (2.50) | 0.535 |
| Oxygen use rate, n (%) | 107 (40.1) | 122 (42.8) | 6 (31.6) | 122 (46.4) | 0.175 |
| HFNC use rate, n (%) | 17 (6.4) | 25 (8.8) | 2 (10.5) | 36 (13.7) | 0.00784 |
| Ventilator use rate, n (%) | 2 (0.7) | 1 (0.4) | 0 (0) | 3 (1.1) | 0.386 |
| Mortality rate, n (%) | 0 (0) | 0 (0) | 0 (0) | 1 (0.4) | NA |
HFNC, high-flow nasal cannula; RSV, respiratory syncytial virus; SD, standard deviation